MDxHealth (NASDAQ:MDXH) Price Target Lowered to $6.00 at Piper Sandler

MDxHealth (NASDAQ:MDXH) had its target price decreased by Piper Sandler from $8.00 to $6.00 in a research report released on Thursday,Benzinga reports. Piper Sandler currently has an overweight rating on the stock.

Separately, Lake Street Capital began coverage on shares of MDxHealth in a research report on Thursday, October 31st. They set a “buy” rating and a $7.00 price objective for the company.

MDxHealth Trading Down 2.9 %

MDxHealth stock traded down $0.06 during midday trading on Thursday, hitting $2.03. 121,458 shares of the stock were exchanged, compared to its average volume of 66,705. MDxHealth has a fifty-two week low of $1.95 and a fifty-two week high of $4.64. The stock has a market capitalization of $3.17 million, a price-to-earnings ratio of -1.34 and a beta of 1.43. The stock’s 50-day simple moving average is $2.29 and its 200 day simple moving average is $2.59.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.13). MDxHealth had a negative return on equity of 987.86% and a negative net margin of 50.54%. The firm had revenue of $23.32 million for the quarter, compared to analyst estimates of $21.48 million. Equities analysts anticipate that MDxHealth will post -1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On MDxHealth

A number of institutional investors have recently made changes to their positions in the stock. OneDigital Investment Advisors LLC increased its position in shares of MDxHealth by 15.3% during the third quarter. OneDigital Investment Advisors LLC now owns 57,726 shares of the company’s stock valued at $120,000 after acquiring an additional 7,656 shares during the last quarter. MVM Partners LLC grew its holdings in shares of MDxHealth by 3.3% in the third quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock valued at $9,706,000 after purchasing an additional 150,000 shares in the last quarter. Finally, Perkins Capital Management Inc. grew its holdings in shares of MDxHealth by 70.7% in the third quarter. Perkins Capital Management Inc. now owns 747,375 shares of the company’s stock valued at $1,555,000 after purchasing an additional 309,500 shares in the last quarter.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.